Back to top
more

Annovis Bio (ANVS)

(Delayed Data from NYSE)

$8.36 USD

8.36
786,199

+1.51 (22.04%)

Updated May 14, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake

by Zacks Equity Research

With NeuBase (NBSE) exploring strategic alternatives to the company, Symetryx joins the company's shareholder base and urges the board to issue a unique $1 per share dividend.

Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up

by Zacks Equity Research

Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies.

BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study

by Zacks Equity Research

Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its CardiAMP cell therapy is unlikely to achieve the primary endpoint for the treatment of heart failure.

Insmed (INSM) Up on Positive Data From MAC Lung Disease Study

by Zacks Equity Research

Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.

AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why

by Zacks Equity Research

AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases.

SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why

by Zacks Equity Research

SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.

FTC Allows Amgen (AMGN) to Proceed With $28B Horizon Buyout

by Zacks Equity Research

Per the settlement terms, Amgen (AMGN) is prohibited from bundling its products with Horizon's Tepezza or Krystexxa. Amgen expects to complete the Horizon acquisition before 2023-end.

InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why

by Zacks Equity Research

Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatment of critically ill COVID-19 patients.

Sage Therapeutics (SAGE) Plunges 46% in a Month: Here's Why

by Zacks Equity Research

The plunge in Sage's (SAGE) shares comes after the FDA declined to approve Zurzuvae in major depressive disorder indication, citing management to conduct more clinical studies.

Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up

by Zacks Equity Research

Acer (ACER) surges as Zevra Therapeutics offers to acquire it for approximately $91 million.

Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate

by Zacks Equity Research

Outlook's (OTLK) shares decline as it receives a complete response letter for Lytenava (ONS-5010), treating wet age-related macular degeneration.

Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug

by Zacks Equity Research

Zai Lab (ZLAB) gains on receiving Breakthrough Therapy designation for repotrectinib from the Center for Drug Evaluation of the National Medical Products Administration in China.

Merck's (MRK) Keytruda Receives EU Nod in Gastric Cancer

by Zacks Equity Research

Following the approval, Merck's (MRK) Keytruda is the first immunotherapy approved in the EU for first-line treatment for HER2-positive advanced gastric cancer in adults whose tumors express PD-L1.

Apellis (APLS) Dips on Layoffs Amid Syfovre Safety Issues

by Zacks Equity Research

Apellis (APLS) plans to initiate restructuring plans to strengthen its commercial portfolio and curb cash burn.

J&J (JNJ) Seeks Full FDA Nod for Balversa in Urothelial Cancer

by Zacks Equity Research

J&J (JNJ) submits a supplemental new drug application to the FDA for full approval of Balversa to treat urothelial carcinoma.

Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why

by Zacks Equity Research

Invivyd's (IVVD) shares rallied almost 18% over the past three months, owing to promising developments in its monoclonal antibody candidate, VYD222, designed to prevent symptomatic COVID-19 infection.

PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why

by Zacks Equity Research

Shares of PDS Biotech (PDSB) show an upward trajectory as the company progresses toward initiating the late-stage development of its lead pipeline candidate.

Esperion (ESPR) Aims to Expand Key Drug Labels for Growth

by Zacks Equity Research

Esperion's (ESPR) non-statin approved drugs uptake has continued to be the growth driver since launch. However, the company is currently facing a conflict with its partner, Daiichi Sankyo, regarding milestone payments.

J&J (JNJ) Seeks Full FDA Nod for Rybrevant in Lung Cancer

by Zacks Equity Research

J&J's (JNJ) FDA filing is based on a late-stage study showing that treatment with Rybrevant plus chemotherapy improved progression-free survival in certain NSCLC patients.

Here's Why You Should Add Corcept (CORT) Stock to Your Portfolio

by Zacks Equity Research

Corcept (CORT), a top-ranked stock, is witnessing incremental sales in its only marketed product, Korlym. It is also making good progress with its promising set of pipeline candidates.

Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate

by Zacks Equity Research

Bionomics (BNOX) gains as it provides updates on further development of its lead pipeline candidate, BNC210, developed for post-traumatic stress disorder and social anxiety disorder.

Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate

by Zacks Equity Research

Fulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its pipeline candidate FTX-6058, to treat patients with sickle cell disease.

Apellis (APLS) Updates on Safety Concerns for Syfovre

by Zacks Equity Research

Apellis' (APLS) shares rise as the company provides updates on safety concerns regarding Syfovre, approved for the treatment of geographic atrophy.

J&J (JNJ) to Keep 9.5% Stake in Kenvue Post Share Exchange

by Zacks Equity Research

J&J's (JNJ) offer to exchange its shares for the shares of Kenvue, its recently-separated consumer healthcare business, gets oversubscribed. The exchange ratio is 8.0324 for every share of J&J.

Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up

by Zacks Equity Research

Timber (TMBR) surges as LEO Pharma offers to acquire it for approximately $36 million.